{"entity":{"id":"nct04138719","kind":"trial","name":"Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer","aka":[],"tldr":"A phase 2 trial of nab-paclitaxel, carboplatin and epirubicin in triple-negative breast cancer, run by Hebei Medical University Fourth Hospital, now recruiting.","summary":"Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer is a phase 2, randomised interventional study registered as NCT04138719 by Hebei Medical University Fourth Hospital, with a registry enrolment figure of 520 participants, started 2019-11-20 and due to reach its primary completion in 2026-10-20. Interventions recorded: Nab-paclitaxel + Carboplatin; Nab-paclitaxel + Epirubicin. Conditions listed: Breast Cancer; Triple-negative Breast Cancer; Nab-paclitaxel. Triple-negative eligibility wording from the registry: \"Histologically confirmed triple negative breast cancer;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT04138719","url":"https://clinicaltrials.gov/study/NCT04138719"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":["cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["nab-paclitaxel","carboplatin","epirubicin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04138719","phase":"2","setting":"Clinical Study of Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer","sponsor":"Hebei Medical University Fourth Hospital","enrolled":520,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04138719/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"epirubicin","kind":"drug","name":"Epirubicin","route":"/drugs/epirubicin/"},{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}